Jasper Therapeutics (JSPR) PT Lowered at RBC Capital as 'BEACON Investigation Raises Further Questions'
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev lowered the price target on Jasper Therapeutics (NASDAQ: JSPR) to $4.00 (from $5.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
